NO20044588L - Nye forbindelser - Google Patents

Nye forbindelser

Info

Publication number: NO20044588L
Authority: NO; Norway
Prior art keywords: new connections; connections; new
Prior art date: 2002-03-27

Application number

NO20044588A

Other languages

English (en)

Other versions

NO329319B1 (no

Inventor

Mervyn Thompson

Christopher Norbert Johnson

Gregor James Macdonald

David R Witty

Stephen Frederick Moss

Mahmood Ahmed

Martin C Jones

Charles Edward Wade

Original Assignee

Glaxo Group Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-03-27

Filing date

2004-10-25

Publication date

2004-10-25

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=28456035&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20044588(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2002-03-27 Priority claimed from GB0207289A external-priority patent/GB0207289D0/en

2002-11-04 Priority claimed from GB0225678A external-priority patent/GB0225678D0/en

2004-10-25 Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd

2004-10-25 Publication of NO20044588L publication Critical patent/NO20044588L/no

2010-09-27 Publication of NO329319B1 publication Critical patent/NO329319B1/no

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/40—Nitrogen atoms attached in position 8
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Psychiatry (AREA)
Addiction (AREA)
Pain & Pain Management (AREA)
Psychology (AREA)
Immunology (AREA)
Obesity (AREA)
Pulmonology (AREA)
Child & Adolescent Psychology (AREA)
Diabetes (AREA)
Hospice & Palliative Care (AREA)
Anesthesiology (AREA)
Hematology (AREA)
Nutrition Science (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Quinoline Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

NO20044588A 2002-03-27 2004-10-25 Kinolinforbindelser, fremgangsmåter for fremstilling derav, farmsøytiske preparater samt anvendelser av forbindelsene NO329319B1 (no)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GB0207289A GB0207289D0 (en)	2002-03-27	2002-03-27	Novel compounds
GB0225678A GB0225678D0 (en)	2002-11-04	2002-11-04	Novel compounds
PCT/EP2003/003197 WO2003080580A2 (en)	2002-03-27	2003-03-25	Quinoline derivatives and their use as 5-ht6 ligands

Publications (2)

Publication Number	Publication Date
NO20044588L true NO20044588L (no)	2004-10-25
NO329319B1 NO329319B1 (no)	2010-09-27

Family

ID=28456035

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20044588A NO329319B1 (no)	2002-03-27	2004-10-25	Kinolinforbindelser, fremgangsmåter for fremstilling derav, farmsøytiske preparater samt anvendelser av forbindelsene

Country Status (27)

Country	Link
US (5)	US7452888B2 (no)
EP (2)	EP1956004B1 (no)
JP (2)	JP4455064B2 (no)
KR (1)	KR101020399B1 (no)
CN (1)	CN1315809C (no)
AR (1)	AR039127A1 (no)
AT (1)	ATE398108T1 (no)
AU (1)	AU2003219103B2 (no)
BR (1)	BRPI0308696B8 (no)
CA (1)	CA2479786C (no)
CY (2)	CY1108313T1 (no)
DE (1)	DE60321558D1 (no)
DK (2)	DK1497266T3 (no)
ES (2)	ES2307919T3 (no)
IL (2)	IL164108A0 (no)
IS (1)	IS2599B (no)
MX (1)	MXPA04009318A (no)
MY (1)	MY138836A (no)
NO (1)	NO329319B1 (no)
NZ (1)	NZ535239A (no)
PL (1)	PL209872B1 (no)
PT (2)	PT1497266E (no)
RU (1)	RU2309154C9 (no)
SI (2)	SI1956004T1 (no)
TW (1)	TWI268928B (no)
WO (1)	WO2003080580A2 (no)
ZA (1)	ZA200407320B (no)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7452888B2 (en) *	2002-03-27	2008-11-18	Glaxo Group Limited	Quinoline derivatives and their use as 5-ht6 ligands
CN100482662C (zh)	2003-02-14	2009-04-29	惠氏公司	作为5-羟基色胺-6配体的杂环基-3-磺酰基氮杂吲哚或-氮杂吲唑衍生物
WO2004074243A2 (en)	2003-02-14	2004-09-02	Wyeth	Heterocyclyl-3-sulfonylindazoles as 5-hydroxytryptamine-6 ligands
MXPA06000795A (es)	2003-07-22	2006-08-23	Arena Pharm Inc	Derivados de diaril y arilheteroaril urea como moduladores del receptor 5-ht2a de serotonina utiles para la profilaxis y tratamiento de desordenes relacionados con el mismo.
GB0320320D0 (en) *	2003-08-29	2003-10-01	Glaxo Group Ltd	Novel compounds
GB0321473D0 (en) *	2003-09-12	2003-10-15	Glaxo Group Ltd	Novel compounds
GB0322510D0 (en) *	2003-09-25	2003-10-29	Glaxo Group Ltd	Novel compounds
GB0322629D0 (en) *	2003-09-26	2003-10-29	Glaxo Group Ltd	Novel compound
GB0407025D0 (en) *	2004-03-29	2004-04-28	Glaxo Group Ltd	Novel compounds
GB0411421D0 (en) *	2004-05-21	2004-06-23	Glaxo Group Ltd	Novel compounds
GB0425548D0 (en) *	2004-11-19	2004-12-22	Glaxo Group Ltd	Radiolabelled ligands
GB0426313D0 (en) *	2004-12-01	2005-01-05	Merck Sharp & Dohme	Therapeutic agents
EP1893560A2 (en)	2005-06-02	2008-03-05	F. Hoffmann-Roche AG	3-methanesulfonylquinolines as gaba-b enhancers
DE602006013828D1 (en)	2005-07-27	2010-06-02	Hoffmann La Roche	4-aryloxy-chinolin-derivate als 5-ht6-modulatoren
GB0519760D0 (en) *	2005-09-28	2005-11-09	Glaxo Group Ltd	Novel compounds
GB0519758D0 (en) *	2005-09-28	2005-11-09	Glaxo Group Ltd	Novel process
GB0519765D0 (en) *	2005-09-28	2005-11-09	Glaxo Group Ltd	Novel compounds
JP2009520014A (ja) *	2005-12-20	2009-05-21	リヒターゲデオンニュルト	ｍＧｌｕＲ５受容体介在障害の治療に有用なキノリン誘導体
AU2007235499A1 (en)	2006-04-05	2007-10-18	Wyeth	Sulfonyl-3-heterocyclylindazole derivatives as 5-hydroxytryptamine-6 ligands
EA017007B1 (ru)	2007-01-08	2012-09-28	Сувен Лайф Сайенсиз Лимитед	Соединения 5-(гетероциклил)алкил-n-(арилсульфонил)индола и их применение в качестве лигандов 5-ht
JP5550352B2 (ja) *	2007-03-15	2014-07-16	ノバルティスアーゲー	有機化合物およびその使用
ES2389958T3 (es) *	2007-03-21	2012-11-05	Glaxo Group Limited	Uso de derivados de quinolina en el tratamiento del dolor
MX2009010243A (es)	2007-03-23	2009-12-14	Abbott Gmbh & Co Kg	Compuestos de quinolina apropiados para tratar trastornos que responden a la modulacion del receptor de serotonina 5-ht6.
ATE513810T1 (de)	2007-05-03	2011-07-15	Suven Life Sciences Ltd	Aminoalkoxy-aryl-sulfonamidverbindungen und ihre verwendung als 5-ht6-liganden
EA016691B1 (ru)	2007-06-18	2012-06-29	Рихтер Гедеон Нирт.	Производные сульфонилхинолина
CN101687866B (zh) *	2007-08-07	2014-06-04	Abbvie德国有限责任两合公司	用于治疗响应于血色素5-ht6受体调节的疾病的喹啉化合物
DK2200980T3 (da)	2007-10-26	2011-11-21	Suven Life Sciences Ltd	Aminoarylsulfonamidforbindelser og deres anvendelse som 5-HT6-ligander
EP2508177A1 (en)	2007-12-12	2012-10-10	Glaxo Group Limited	Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline
WO2009101018A2 (en) *	2008-02-15	2009-08-20	F. Hoffmann-La Roche Ag	3-alkyl-piperazine derivatives and uses thereof
US20110021538A1 (en)	2008-04-02	2011-01-27	Arena Pharmaceuticals, Inc.	Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
US20100041663A1 (en) *	2008-07-18	2010-02-18	Novartis Ag	Organic Compounds as Smo Inhibitors
WO2010032257A1 (en)	2008-09-17	2010-03-25	Suven Life Sciences Limited	Aryl indolyl sulfonamide compounds and their use as 5-ht6 ligands
CN102159564B (zh)	2008-09-17	2014-06-18	苏文生命科学有限公司	芳基磺酰胺胺化合物及它们作为5-ht6配体的用途
WO2010062321A1 (en)	2008-10-28	2010-06-03	Arena Pharmaceuticals, Inc.	Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea and crystalline forms related thereto
NZ622505A (en)	2009-06-29	2015-12-24	Agios Pharmaceuticals Inc	Therapeutic compounds and compositions
CU24144B1 (es) *	2010-01-04	2016-01-29	Nippon Soda Co	Compuesto heterocíclico conteniendo nitrógeno y fungicida para el uso en agricultura y jardinería
US9018231B2 (en)	2010-01-05	2015-04-28	Suven Life Sciences Limited	Sulfone compounds as 5-HT6 receptor ligands
RU2443697C1 (ru) *	2010-12-21	2012-02-27	Александр Васильевич Иващенко	Замещенные метил-амины, антагонисты серотониновых 5-ht6 рецепторов, способы получения и применения
KR101250606B1 (ko) *	2011-01-24	2013-04-03	이화여자대학교 산학협력단	5-ｈｔ６ 수용체 억제 작용을 갖는 신규한 벤조티아졸 및 벤즈이소티아졸유도체, 이의 제조 방법 및 이를 포함하는 약학적 조성물
AR086411A1 (es)	2011-05-20	2013-12-11	Nippon Soda Co	Compuesto heterociclico conteniendo nitrogeno y fungicida para el uso en agricultura y jardineria
EP3718547A1 (en)	2011-10-03	2020-10-07	The University of Utah Research Foundation	Application of 5-ht6 receptor antagonists for the alleviation of cognitive deficits of down syndrome
RU2500672C1 (ru) *	2012-10-25	2013-12-10	Андрей Александрович Иващенко	(3-арилсульфонилхинолин-8-ил)-диалкил-амины - селективные антагонисты серотониновых 5-ht6 рецепторов, способы их получения и применения
US9302992B2 (en)	2013-04-02	2016-04-05	Annji Pharmaceutical Co., Ltd.	Multifunctional quinoline derivatives as anti-neurodegenerative agents
KR101802048B1 (ko)	2013-04-02	2017-12-28	안지 파마슈티컬 코퍼레이션 리미티드	항신경퇴행성제로서의 다작용성 퀴놀린 유도체
KR20180021693A (ko) *	2015-05-07	2018-03-05	엑소반트 사이언시즈 게엠베하	신경퇴행성 질환을 치료하는 조성물 및 방법
RU2017145976A (ru)	2015-06-12	2019-07-15	Аксовант Сайенсиз Гмбх	Производные диарил- и арилгетероарилмочевины, применимые для профилактики и лечения нарушения поведения во время REM-фазы сна
EP3322415A4 (en)	2015-07-15	2019-03-13	Axovant Sciences GmbH	DIARYL AND ARYLHETEROARYL UREA DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR FOR PROPHYLAXIS AND TREATMENT OF HALLUCINATIONS RELATED TO A NEUROGENERATIVE DISEASE
AR106515A1 (es)	2015-10-29	2018-01-24	Bayer Cropscience Ag	Sililfenoxiheterociclos trisustituidos y análogos
CN109069450A (zh) *	2016-02-05	2018-12-21	法奈克斯公司	神经障碍的新的组合疗法
US10160744B2 (en)	2016-03-14	2018-12-25	AbbVie Deutschland GmbH & Co. KG	Quinoline compounds suitable for treating disorders that respond to the modulation of the serotonin 5-HT6 receptor
CN108290842B (zh) *	2016-05-27	2021-04-06	深圳市塔吉瑞生物医药有限公司	一种取代的喹啉化合物及其药物组合物
WO2018102824A1 (en) *	2016-12-02	2018-06-07	Axovant Sciences Gmbh	Methods for treating neurodegenerative disease
KR20210076224A (ko)	2019-12-13	2021-06-24	주식회사 에피바이오텍	퀴놀린 유도체를 포함하는 탈모의 예방 또는 치료용 조성물
KR102281647B1 (ko) *	2020-12-09	2021-07-30	메디케어제약 주식회사	피페라진-퀴놀린 유도체의 제조방법

Family Cites Families (90)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US708469A (en) *	1901-08-27	1902-09-02	George Lafayette Caldwell	Stroke-regulating mechanism for glass-presses, &c.
JPH02262627A (ja)	1988-12-08	1990-10-25	Japan Synthetic Rubber Co Ltd	有機非線形光学素子
SI9200377A (en) *	1992-12-11	1994-06-30	Krka	Process for the preparation of 1-substituted 6-fluoro-4-oxo-7-(1-piperazinyl)-1,4-dihydroquinoline-3-carboxilic acid, novel intermediate used in this process and process for its preparation
GB9300147D0 (en)	1993-01-06	1993-03-03	Minnesota Mining & Mfg	Photothermographic materials
GB9311790D0 (en)	1993-06-08	1993-07-28	Minnesota Mining & Mfg	Photothermographic materials
US5596001A (en)	1993-10-25	1997-01-21	Pfizer Inc.	4-aryl-3-(heteroarylureido)quinoline derivatves
DK122693D0 (da)	1993-10-29	1993-10-29	Hempels Skibsfarve Fab J C	Marin struktur
US5576338A (en)	1995-02-15	1996-11-19	Merck Frosst Canada, Inc.	Bis (biaryl) compounds as inhibitors of leukotriene biosynthesis
AUPN842196A0 (en)	1996-03-05	1996-03-28	Fujisawa Pharmaceutical Co., Ltd.	New compound
FR2750988B1 (fr)	1996-07-11	1998-09-18	Adir	Nouveaux derives de 2-(1h)-quinoleinone, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US20010051719A1 (en)	1996-12-19	2001-12-13	Smithkline Beecham P.L.C.	Novel compounds
DZ2376A1 (fr)	1996-12-19	2002-12-28	Smithkline Beecham Plc	Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant.
DE59803962D1 (de)	1997-03-25	2002-06-06	Ciba Sc Holding Ag	Polycyclische Verbindungen
CA2272291C (en)	1997-04-22	2008-06-17	Janssen Pharmaceutica N.V.	Crf antagonistic quino- and quinazolines
EA004103B1 (ru)	1997-05-28	2003-12-25	Авентис Фармасьютикалз Продактс Инк.	ХИНОЛИНОВЫЕ И ХИНОКСАЛИНОВЫЕ СОЕДИНЕНИЯ, ИНГИБИРУЮЩИЕ ТИРОЗИНКИНАЗЫ ТРОМБОЦИТАРНОГО ФАКТОРА РОСТА И/ИЛИ p56
US6103905A (en)	1997-06-19	2000-08-15	Sepracor, Inc.	Quinoline-indole antimicrobial agents, uses and compositions related thereto
US6207679B1 (en)	1997-06-19	2001-03-27	Sepracor, Inc.	Antimicrobial agents uses and compositions related thereto
US6172084B1 (en)	1997-06-19	2001-01-09	Sepracor, Inc.	Quinoline-indole antimicrobial agents, uses and compositions related thereto
US6376670B1 (en)	1997-06-19	2002-04-23	Sepracor Inc.	Quinoline-indole antimicrobial agents, uses and compositions related thereto
PL338016A1 (en)	1997-07-11	2000-09-25	Smithkline Beecham Plc	Novel chemical compounds
SI0930302T1 (en) *	1998-01-16	2003-10-31	F. Hoffmann-La Roche Ag	Benzosulfone derivatives
GB9801392D0 (en)	1998-01-22	1998-03-18	Smithkline Beecham Plc	Novel compounds
GB9803411D0 (en)	1998-02-18	1998-04-15	Smithkline Beecham Plc	Novel compounds
US6100291A (en)	1998-03-16	2000-08-08	Allelix Biopharmaceuticals Inc.	Pyrrolidine-indole compounds having 5-HT6 affinity
US6251893B1 (en) *	1998-06-15	2001-06-26	Nps Allelix Corp.	Bicyclic piperidine and piperazine compounds having 5-HT6 receptor affinity
GB9818916D0 (en)	1998-08-28	1998-10-21	Smithkline Beecham Plc	Use
GB9819382D0 (en)	1998-09-04	1998-10-28	Cerebrus Ltd	Chemical compounds I
GB9820113D0 (en)	1998-09-15	1998-11-11	Merck Sharp & Dohme	Therapeutic agents
US6403808B1 (en)	1999-12-10	2002-06-11	Virginia Commonwealth University	Selective 5-HT6 receptor ligands
WO2000042026A1 (en)	1999-01-15	2000-07-20	Novo Nordisk A/S	Non-peptide glp-1 agonists
CA2368455A1 (en)	1999-03-29	2000-10-05	Neurogen Corporation	4-substituted quinoline derivatives as nk-3 and/or gaba(a) receptor ligands
CA2370147C (en) *	1999-04-21	2009-07-28	Allelix Biopharmaceuticals Inc.	Piperidine-indole compounds having 5-ht6 affinity
AU4802500A (en)	1999-04-26	2000-11-10	Neurogen Corporation	2-aminoquinolinecarboxamides: neurokinin receptor ligands
US6566372B1 (en)	1999-08-27	2003-05-20	Ligand Pharmaceuticals Incorporated	Bicyclic androgen and progesterone receptor modulator compounds and methods
MY125942A (en)	1999-09-07	2006-09-29	Upjohn Co	Aminoalkoxy carbazoles for the treatment of cns diseases
GB9926302D0 (en) *	1999-11-05	2000-01-12	Smithkline Beecham Plc	Novel compounds
AU1542201A (en)	1999-11-05	2001-05-14	Nps Allelix Corp.	Compounds having 5-HT6 receptor antagonist activity
UA75055C2 (uk)	1999-11-30	2006-03-15	Пфайзер Продактс Інк.	Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі
US6310212B1 (en)	2000-03-28	2001-10-30	Neurogen Corporation	4-substituted quinoline derivatives
PE20020063A1 (es)	2000-06-20	2002-01-30	Upjohn Co	Bis-arilsulfonas como ligandos del receptor de 5-ht
SE0002754D0 (sv)	2000-07-21	2000-07-21	Pharmacia & Upjohn Ab	New pharmaceutical combination formulation and method of treatment with the combination
GB0021450D0 (en)	2000-08-31	2000-10-18	Smithkline Beecham Plc	Novel compounds
US6576644B2 (en)	2000-09-06	2003-06-10	Bristol-Myers Squibb Co.	Quinoline inhibitors of cGMP phosphodiesterase
EP1332133B1 (en)	2000-10-02	2008-07-09	Janssen Pharmaceutica N.V.	Metabotropic glutamate receptor antagonists
WO2002032863A1 (en)	2000-10-20	2002-04-25	Biovitrum Ab	2-, 3-, 4-, or 5-substituted-n1-(benzensulfonyl)indoles and their use in therapy
CN1222511C (zh)	2000-11-02	2005-10-12	惠氏公司	作为5－羟色胺－6配体的1－芳基－或1－烷基磺酰基－杂环基吲哚
WO2002042293A1 (en)	2000-11-21	2002-05-30	Smithkline Beecham P.L.C.	Isoquinoline derivatives useful in the treatment of cns disorders
ATE337780T1 (de)	2000-11-24	2006-09-15	Smithkline Beecham Plc	Indoly-lsulphonyl-verbindungen zur behandlung von störungen des zns
ES2188344B1 (es)	2000-11-29	2004-09-16	Laboratorios Vita, S.A.	Compuestos derivados de benzotiofeno, su procedimiento de obtencion y utilizacion de los mismos.
GB0111186D0 (en)	2001-05-08	2001-06-27	Smithkline Beecham Plc	Novel compounds
KR100600240B1 (ko)	2001-06-07	2006-07-13	에프. 호프만-라 로슈 아게	5-ｈｔ6 수용체 친화도를 갖는 신규한 인돌 유도체
ATE331707T1 (de)	2001-06-15	2006-07-15	Hoffmann La Roche	4 piperazinylindolderivate mit affinität zum 5- ht6-rezeptor
ITRM20010356A1 (it)	2001-06-21	2002-12-23	Sigma Tau Ind Farmaceuti	"5-alogeno derivati della triptamina utili come ligandi del recettore5-ht6 e/o 5-ht7 della serotonina.
BR0211561A (pt)	2001-08-03	2004-11-30	Upjohn Co	Compostos e composições de 5-arilsulfonil indóis tendo afinidade para receptor 5-ht6 e seus usos
EP1414442A1 (en)	2001-08-07	2004-05-06	Smithkline Beecham Plc	3-arylsulfonyl-7-piperazinyl- indoles, -benzofurans and -benzothiophenes with 5-ht6 receptor affinity for treating cns disorders
CA2456250A1 (en)	2001-08-10	2003-02-20	F. Hoffmann-La Roche Ag	Arylsulfonyl derivatives with 5-ht6 receptor affinity
ES2398434T3 (es)	2001-08-31	2013-03-19	Novartis Ag	Isómeros ópticos de un metabolito de iloperidona
SE0103649D0 (sv)	2001-11-01	2001-11-01	Astrazeneca Ab	Therapeutic quinoline compounds
WO2003062205A1 (en)	2001-12-21	2003-07-31	Smithkline Beecham P.L.C.	7-sulfonyl-3-benzazepine derivatives as modulators of the dopamine receptor and their use for the treatment of cns disorders
GB0202679D0 (en)	2002-02-05	2002-03-20	Glaxo Group Ltd	Novel compounds
EP1471912A1 (en)	2002-02-05	2004-11-03	Glaxo Group Limited	Method of promoting neuronal growth
TW200306843A (en)	2002-02-13	2003-12-01	Glaxo Group Ltd	Novel compounds
DE10207844A1 (de)	2002-02-15	2003-09-04	Schering Ag	1-Phenyl-2-heteroaryl-substituierte Benzimidazolderivate, deren Verwendung zur Herstellung von Arzneimitteln sowie diese Derivate enthaltende pharmazeutische Präparate
MXPA04008104A (es)	2002-02-22	2006-05-25	Upjohn Co	Derivados de arilsulfona.
US7452888B2 (en) *	2002-03-27	2008-11-18	Glaxo Group Limited	Quinoline derivatives and their use as 5-ht6 ligands
US20050124626A1 (en)	2002-03-27	2005-06-09	Johnson Christopher N.	Novel compounds
DE10221183A1 (de)	2002-05-13	2003-12-04	Max Planck Gesellschaft	Phosphatidyl-oligo-glycerine und Strukturanaloga
JP4307377B2 (ja)	2002-05-13	2009-08-05	エフ．ホフマン−ラロシュアーゲー	５−ｈｔ６モジュレーターとしてのベンゾオキサジン誘導体及びそれらの使用
EP1513809A1 (en)	2002-06-05	2005-03-16	F. Hoffmann-La Roche Ag	1-sulfonyl-4-aminoalkoxy indole derivatives as 5-ht6-receptor modulators for the treatment of cns-disorders
JP4754821B2 (ja)	2002-06-20	2011-08-24	プロキシマゲン・リミテッド	肥満症、ｉｉ型糖尿病およびｃｎｓ障害の治療に有用な新規化合物
AU2003243091A1 (en)	2002-06-20	2004-01-06	Biovitrum Ab (Publ)	New compounds useful for the treatment of obesity, type ii diabetes and cns disorders
ES2311721T3 (es)	2002-09-17	2009-02-16	F. Hoffmann-La Roche Ag	Indoles sustituidos en posicion 2,4 y su empleo como moduladores de 5-ht6.
DK1587788T3 (da)	2002-09-17	2007-09-24	Hoffmann La Roche	2,7-substituerede indoler og anvendelsen deraf som 5-HT6-modulatorer
DE60309498T2 (de)	2002-10-18	2007-08-30	F. Hoffmann-La Roche Ag	4-piperazinylbenzolsulfonyl-indole mit 5-ht6 rezeptor-affinität
PL377770A1 (pl)	2002-11-08	2006-02-20	F. Hoffmann-La Roche Ag	Podstawione benzoksazynony i ich zastosowanie
CN1713908B (zh)	2002-12-03	2010-05-12	弗·哈夫曼-拉罗切有限公司	作为5-ht6-受体配体用于治疗中枢神经系统病症的氨基烷氧基吲哚
CN100482662C (zh)	2003-02-14	2009-04-29	惠氏公司	作为5-羟基色胺-6配体的杂环基-3-磺酰基氮杂吲哚或-氮杂吲唑衍生物
BRPI0407976A (pt)	2003-03-03	2006-03-07	Hoffmann La Roche	tetrahidroisoquinolinas substituìdas em 2,5 e 2,6 para uso como moduladores de 5-ht6
TWI289141B (en)	2003-03-11	2007-11-01	Hoffmann La Roche F. Ag.	Quinolinone derivatives and uses thereof
GB0305575D0 (en)	2003-03-11	2003-04-16	Glaxo Group Ltd	Novel compounds
GB0320320D0 (en)	2003-08-29	2003-10-01	Glaxo Group Ltd	Novel compounds
GB0321473D0 (en)	2003-09-12	2003-10-15	Glaxo Group Ltd	Novel compounds
GB0322510D0 (en)	2003-09-25	2003-10-29	Glaxo Group Ltd	Novel compounds
GB0322629D0 (en)	2003-09-26	2003-10-29	Glaxo Group Ltd	Novel compound
GB0407025D0 (en)	2004-03-29	2004-04-28	Glaxo Group Ltd	Novel compounds
GB0411421D0 (en)	2004-05-21	2004-06-23	Glaxo Group Ltd	Novel compounds
GB0422263D0 (en)	2004-10-07	2004-11-10	Glaxo Group Ltd	Novel compounds
GB0519765D0 (en)	2005-09-28	2005-11-09	Glaxo Group Ltd	Novel compounds
GB0519758D0 (en)	2005-09-28	2005-11-09	Glaxo Group Ltd	Novel process
GB0519760D0 (en)	2005-09-28	2005-11-09	Glaxo Group Ltd	Novel compounds

2003
- 2003-03-25 US US10/509,078 patent/US7452888B2/en not_active Expired - Lifetime
- 2003-03-25 PL PL374378A patent/PL209872B1/pl unknown
- 2003-03-25 AT AT03714889T patent/ATE398108T1/de active
- 2003-03-25 IL IL16410803A patent/IL164108A0/xx unknown
- 2003-03-25 ES ES03714889T patent/ES2307919T3/es not_active Expired - Lifetime
- 2003-03-25 TW TW092106558A patent/TWI268928B/zh not_active IP Right Cessation
- 2003-03-25 SI SI200332178T patent/SI1956004T1/sl unknown
- 2003-03-25 CN CNB038116448A patent/CN1315809C/zh not_active Expired - Fee Related
- 2003-03-25 AU AU2003219103A patent/AU2003219103B2/en not_active Ceased
- 2003-03-25 KR KR1020047015297A patent/KR101020399B1/ko not_active Expired - Fee Related
- 2003-03-25 EP EP08157490A patent/EP1956004B1/en not_active Expired - Lifetime
- 2003-03-25 EP EP03714889A patent/EP1497266B1/en not_active Expired - Lifetime
- 2003-03-25 NZ NZ535239A patent/NZ535239A/en not_active IP Right Cessation
- 2003-03-25 WO PCT/EP2003/003197 patent/WO2003080580A2/en not_active Ceased
- 2003-03-25 BR BRPI0308696A patent/BRPI0308696B8/pt not_active IP Right Cessation
- 2003-03-25 PT PT03714889T patent/PT1497266E/pt unknown
- 2003-03-25 RU RU2004131641/04A patent/RU2309154C9/ru not_active IP Right Cessation
- 2003-03-25 ES ES08157490T patent/ES2386828T3/es not_active Expired - Lifetime
- 2003-03-25 MY MYPI20031054A patent/MY138836A/en unknown
- 2003-03-25 AR ARP030101028A patent/AR039127A1/es not_active Application Discontinuation
- 2003-03-25 DK DK03714889T patent/DK1497266T3/da active
- 2003-03-25 PT PT08157490T patent/PT1956004E/pt unknown
- 2003-03-25 MX MXPA04009318A patent/MXPA04009318A/es active IP Right Grant
- 2003-03-25 CA CA2479786A patent/CA2479786C/en not_active Expired - Fee Related
- 2003-03-25 SI SI200331326T patent/SI1497266T1/sl unknown
- 2003-03-25 DK DK08157490.7T patent/DK1956004T3/da active
- 2003-03-25 JP JP2003578335A patent/JP4455064B2/ja not_active Expired - Fee Related
- 2003-03-25 DE DE60321558T patent/DE60321558D1/de not_active Expired - Lifetime
2004
- 2004-09-13 ZA ZA2004/07320A patent/ZA200407320B/en unknown
- 2004-09-14 IL IL164108A patent/IL164108A/en not_active IP Right Cessation
- 2004-09-24 IS IS7470A patent/IS2599B/is unknown
- 2004-10-25 NO NO20044588A patent/NO329319B1/no not_active IP Right Cessation
2008
- 2008-09-03 CY CY20081100943T patent/CY1108313T1/el unknown
- 2008-09-05 US US12/205,079 patent/US7601837B2/en not_active Expired - Fee Related
2009
- 2009-05-25 JP JP2009125459A patent/JP5091913B2/ja not_active Expired - Fee Related
- 2009-08-14 US US12/541,456 patent/US7799774B2/en not_active Expired - Fee Related
2010
- 2010-07-30 US US12/847,039 patent/US7977337B2/en not_active Expired - Fee Related
2011
- 2011-06-03 US US13/152,356 patent/US8236947B2/en not_active Expired - Fee Related
2012
- 2012-09-05 CY CY20121100804T patent/CY1113306T1/el unknown

Also Published As

Publication number	Publication date
TW200403224A (en)	2004-03-01
US20090298841A1 (en)	2009-12-03
BR0308696A (pt)	2005-01-25
JP4455064B2 (ja)	2010-04-21
US20090036682A1 (en)	2009-02-05
CA2479786C (en)	2011-11-29
US7601837B2 (en)	2009-10-13
JP5091913B2 (ja)	2012-12-05
DK1956004T3 (da)	2012-08-06
WO2003080580A3 (en)	2004-02-05
AU2003219103B2 (en)	2008-10-23
WO2003080580A2 (en)	2003-10-02
JP2009235080A (ja)	2009-10-15
NZ535239A (en)	2008-03-28
DE60321558D1 (de)	2008-07-24
IL164108A0 (en)	2005-12-18
US7977337B2 (en)	2011-07-12
RU2004131641A (ru)	2005-06-27
BRPI0308696B1 (pt)	2019-07-16
CY1113306T1 (el)	2016-04-13
TWI268928B (en)	2006-12-21
EP1497266A2 (en)	2005-01-19
HK1074439A1 (en)	2005-11-11
ES2307919T3 (es)	2008-12-01
BRPI0308696B8 (pt)	2021-05-25
US7799774B2 (en)	2010-09-21
JP2005531518A (ja)	2005-10-20
US20050124628A1 (en)	2005-06-09
EP1956004A1 (en)	2008-08-13
RU2309154C9 (ru)	2016-09-27
MY138836A (en)	2009-07-31
PL374378A1 (en)	2005-10-17
IS7470A (is)	2004-09-24
CY1108313T1 (el)	2014-02-12
PL209872B1 (pl)	2011-10-31
PT1956004E (pt)	2012-08-31
KR20040094874A (ko)	2004-11-10
CA2479786A1 (en)	2003-10-02
US7452888B2 (en)	2008-11-18
ZA200407320B (en)	2005-11-30
IS2599B (is)	2010-04-15
NO329319B1 (no)	2010-09-27
US20110237792A1 (en)	2011-09-29
AR039127A1 (es)	2005-02-09
PT1497266E (pt)	2008-09-10
CN1656075A (zh)	2005-08-17
EP1497266B1 (en)	2008-06-11
CN1315809C (zh)	2007-05-16
KR101020399B1 (ko)	2011-03-08
SI1956004T1 (sl)	2012-09-28
BRPI0308696A8 (pt)	2017-04-11
RU2309154C2 (ru)	2007-10-27
US20100305107A1 (en)	2010-12-02
DK1497266T3 (da)	2008-10-06
ES2386828T3 (es)	2012-08-31
ATE398108T1 (de)	2008-07-15
US8236947B2 (en)	2012-08-07
AU2003219103A1 (en)	2003-10-08
EP1956004B1 (en)	2012-06-13
MXPA04009318A (es)	2005-01-25
SI1497266T1 (sl)	2008-10-31
IL164108A (en)	2010-05-31

Publication	Publication Date	Title
NO20044588L (no)	2004-10-25	Nye forbindelser
NO20044432L (no)	2004-10-19	Nye forbindelser
NO20055219D0 (no)	2005-11-04	Nye forbindelser
NO20040014L (no)	2004-03-02	Nye forbindelser
NO20041003L (no)	2004-06-04	Nye forbindelser
NO20034665L (no)	2003-12-10	Nye forbindelser
NO20035428D0 (no)	2003-12-05	Nye anti-ineffektiver
NO20034992D0 (no)	2003-11-10	Nye 4-aninlinokinolin-3-karboksamider
NO20054224D0 (no)	2005-09-12	Nye 2-pyridinkarboksamidderivater
DE60207371D1 (de)	2005-12-22	Stumpfvermahlungsgerät
DE50212360D1 (de)	2008-07-24	Anfahrhilfesteuerungsvorrichtung
DE60320334D1 (de)	2008-05-29	Klebwalzereiniger
NO20044046L (no)	2004-11-15	Substituerte hydroksyetylaminer
NO20034970D0 (no)	2003-11-07	Nye arylheteroalkylaminderivater
DE60333552D1 (de)	2010-09-09	Münzverarbeitungssystem
DE60325671D1 (de)	2009-02-26	Bilderzeugunsgerät
NO20043595L (no)	2004-10-20	Nye kortikosteroider
DE60310714D1 (de)	2007-02-08	Etonogestrelester
NO20041185L (no)	2004-03-19	Nye sykloheksylsulfoner
ATE496887T1 (de)	2011-02-15	Substituierte 5-aminomethyl-1h-pyrrol-2-carbons ureamide
DE60309990D1 (de)	2007-01-11	Schraubbefestigungsstruktur
DE60329596D1 (de)	2009-11-19	Währungsvalidierer
DE60307236D1 (de)	2006-09-14	Luftgurtaufblasvorrichtung
DE60332551D1 (de)	2010-06-24	Ic-tag
NO20026285D0 (no)	2002-12-30	Nye peptider

Legal Events

Date	Code	Title	Description
2013-05-21	CHAD	Change of the owner's name or address (par. 44 patent law, par. patentforskriften)	Owner name: GLAXO GROUP LTD, GB
2015-08-17	CHAD	Change of the owner's name or address (par. 44 patent law, par. patentforskriften)	Owner name: AXOVANT SCIENCES LTD., BM
2017-02-13	CHAD	Change of the owner's name or address (par. 44 patent law, par. patentforskriften)	Owner name: AXOVANT SCIENCES GMBH, CH
2020-10-26	MM1K	Lapsed by not paying the annual fees